Oncology Based In-Vivo CRO Market Growth Accelerates: Strategic Forecast Predicts $2.28 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Oncology Based In-Vivo CRO Industry Market Size Be by 2025?
The in-vivo CRO market within oncology has experienced robust growth lately. The market, which is projected to escalate from $1.39 billion in 2024 to $1.5 billion in 2025, is expected to grow at a compound annual growth rate (CAGR) of 8.0%. The growth during the historical period can be credited to factors such as the heightened focus on oncology treatments, rising cancer occurrences, a shift toward personalized healthcare, the expansion of the pharmaceutical sector, and the need for therapies aimed at specific targets.

What's the Long-Term Growth Forecast for the Oncology Based In-Vivo CRO Market Size Through 2029?
The in-vivo CRO market, with a focus on oncology, is set for dramatic expansion in coming years. Its projected growth will reach $2.28 billion by 2029, with a compounded annual growth rate (CAGR) of 10.9%. This predicted growth during the forecast period can be attributed to the emergence of new market possibilities, a move towards immuno-oncology treatments, an increase in oncology clinical trials, precision medicine, and individualized treatments. Key trends to watch out for in the forecast period include a greater emphasis on regenerative medicine and cell therapies, a need for speedier drug development, digitalization and data analysis, attention on tumor microenvironments, and a rise in biologics and immunotherapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

What Are the Key Growth Drivers Fueling the Oncology Based In-Vivo CRO Market Expansion?
The proliferation of cancer is anticipated to drive the expansion of the oncology-based in-vivo CRO market. This disease, which manifests as abnormal cells rapidly dividing out of control, can originate in any organ or tissue and spread throughout the body via the bloodstream and lymphatic system. Cancer's treatment and diagnosis necessitate the use of innovative drugs and devices which must undergo numerous preclinical trials, clinical trials, and regulatory processes before being released into the market. Companies known as Oncology in-vivo-based CROs are engaged by sponsor firms to provide research services, which can include complete or partial assistance in executing a preclinical in-vivo study with living organisms before human testing begins. Along with the escalating occurrence of cancer, the demand for pioneering treatments and therapies is also on the rise, contributing to the growth of the in-vivo CRO market within oncology. For example, the American Cancer Society reported approximately 609,000 cancer-related fatalities and 1.9 million new cancer diagnoses within the US in 2022. It is believed that this figure will marginally increase to an estimated 620,000 cancer deaths in 2024. Therefore, the escalating occurrence of cancer is stimulating the development of the oncology-based in-vitro CRO market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

What Are the Key Trends Driving Oncology Based In-Vivo CRO Market Growth?
Companies in the oncology-based in vivo CRO market are emphasizing personalized oncology models to strengthen their market position. For example, in 2022, Charles River Laboratories, a U.S.-based life sciences firm, launched the OncoMouse platform, which incorporates patient-derived xenografts (PDXs) for tailored cancer treatment strategies. The platform features high-throughput screening, real-time tumor monitoring, and integrated data analytics to optimize individualized therapeutic protocols, reflecting a shift toward patient-specific cancer research.

How Is the Oncology Based In-Vivo CRO Market Segmented?
The oncology based in-vivo cro market covered in this report is segmented -

1) By Indication: Blood Cancer, Solid Tumors, Other Indications
2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models
3) By Application: Hospitals, Rehabilitation Centers

Subsegments:
1) By Blood Cancer: Leukemia, Lymphoma, Myeloma
2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Solid Tumors
3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas, Other Specific Indications

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Which Companies Are Leading the Charge in Oncology Based In-Vivo CRO Market Innovation?
Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

Which Regions Are Leading the Global Oncology Based In-Vivo CRO Market in Revenue?
North America was the largest region in the oncology-based in-vivo CRO market in 2024.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology-based in-vivo CRO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10521

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.